30S.F SANIONA AB (PUBL)

Healthcare Biotechnology Frankfurt Exchange
1.05 EUR
Close of Nov 11, 2026
0.7760 2.58
Market cap
EUR 145M
P/E
8.8x
P/B
2.93x
ROE
-38.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 30S.F undervalued?

Graham number
Price1.05
Graham value0.9854
Premium7.0%

30S.F trades 7.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SANIONA AB (PUBL) fundamental analysis

No fundamental analysis for SANIONA AB (PUBL) yet.

SANIONA AB (PUBL) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SANIONA AB (PUBL)

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investi…

Full company profile